Abstract
Sequence variants in fibroblast growth factor 20 (FGF20) have been reported to be associated with Parkinson’s disease (PD). We genotyped the rs591323 variant in a total of 2220 Han Chinese subjects, including 1051 patients with sporadic PD and 1169 controls, to investigate the association between rs591323 and the risk of PD. In addition, we also conducted a stratified analysis according to age at onset of PD and compared the clinical characteristics of AA + AG subjects with GG subjects. In this study, we confirmed that the A allele of rs591323 in FGF20 reduces the risk of developing sporadic PD (P = 0.013). Additionally, subjects with the AA + AG genotype have a reduced risk compared to individuals with the GG genotype (P = 0.024). This association was significant among females (P = 0.036), but was not significant among males (P = 0.266). Furthermore, no significant association was observed among either the early-onset PD group (P = 0.051) or the late-onset PD group (P = 0.187). Moreover, we demonstrated that the AA + AG subjects could not be distinguished from the GG subjects based on their clinical features. Our study is the first to demonstrate that FGF20 (rs591323) is associated with a lower risk of PD in a Southern Han Chinese population from mainland China.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348(14):1356–1364
Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144
Pihlstrom L et al (2013) Supportive evidence for 11 loci from genome-wide association studies in Parkinson’s disease. Neurobiol Aging 34(6):1708 (e7–13)
Nalls MA et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46(9):989–993
International Parkinson’s Disease Genomics C, Wellcome Trust Case Control (2011) A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genet 7(6):e1002142
Pan J et al (2012) Fibroblast growth factor 20 (FGF20) polymorphism is a risk factor for Parkinson’s disease in Chinese population. Parkinsonism Relat Disord 18(5):629–631
Satake W et al (2007) Fibroblast growth factor 20 gene and Parkinson’s disease in the Japanese population. Neuroreport 18(9):937–940
Clarimon J et al (2005) Lack of evidence for a genetic association between FGF20 and Parkinson’s disease in Finnish and Greek patients. BMC Neurol 5:11
Rajput DR (1993) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 56(8):938–939
Jeffers M et al (2001) Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res 61(7):3131–3138
Van der Walt JM et al (2004) Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 74(6):1121–1127
Wang G et al (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82(2):283–289
Pankratz N et al (2003) Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet 12(20):2599–2608
Itoh N, Ohta H (2013) Roles of FGF20 in dopaminergic neurons and Parkinson’s disease. Front Mol Neurosci 6:15
Sleeman IJ, Boshoff EL, Duty S (2012) Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Neuropharmacology 63(7):1268–1277
Zhu R et al (2014) Fibroblast growth factor 20 (FGF20) gene polymorphism and risk of Parkinson’s disease: a meta-analysis. Neurol Sci 35(12):1889–1894
Haghnejad L et al (2015) Variation in the miRNA-433 binding site of FGF20 is a risk factor for Parkinson’s disease in Iranian population. J Neurol Sci 355(1–2):72–74
De Mena L et al (2010) FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson’s disease in Spanish patients. Neurosci Lett 479(1):22–25
Xu X et al (2013) Fibroblast growth factor 20 polymorphism in sporadic Parkinson’s disease in Northern Han Chinese. J Clin Neurosci 20(11):1588–1590
Jing CC et al (2015) Screening of polymorphisms located in the FGF20 and TMEM175 genes in North Chinese Parkinson’s disease patients. Genet Mol Res 14(4):13679–13687
Liu ZH et al (2015) Analysis of several loci from genome-wide association studies in Parkinson’s disease in mainland China. Neurosci Lett 587:68–71
Kara E et al (2014) Assessment of Parkinson’s disease risk loci in Greece. Neurobiol Aging 35(2):442 (e9-442 e16)
Lill CM, Bertram L (2011) Towards unveiling the genetics of neurodegenerative diseases. Semin Neurol 31(5):531–541
Adams HH et al (2015) Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimers Dement 11(11):1277–1285
Acknowledgements
The study was supported by the Science & Technology Department of Sichuan Province (number 2013SZ0003). We gratefully acknowledge Professor Dong Zhou, Li He, Guanggu Yuan, and Yingru Gou. We would also like to thank Wenjuan Yu, Xueli Chang, Xueye Mao, Dongmei Zhao, Jinhong Zhang, and Qiao Liao for their help.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Nothing to declare.
Additional information
Rong Peng: Grant sponsors by West China Hospital of Sichuan University and Science & Technology Department of Sichuan Province (No. 2013SZ0003).
Rights and permissions
About this article
Cite this article
Sun, XY., Wang, L., Cheng, L. et al. Genetic analysis of FGF20 in Chinese patients with Parkinson’s disease. Neurol Sci 38, 887–891 (2017). https://doi.org/10.1007/s10072-017-2868-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-017-2868-y